Manhouly Phouthachack, | |
839 Farmington Ave, Bristol, CT 06010-3922 | |
(866) 389-2727 | |
Not Available |
Full Name | Manhouly Phouthachack |
---|---|
Gender | Female |
Speciality | Nurse Practitioner |
Experience | 17 Years |
Location | 839 Farmington Ave, Bristol, Connecticut |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1295965481 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363LF0000X | Nurse Practitioner - Family | 004098 (Connecticut) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Mc Diagnostic Of Connecticut, P.c. | 0941382113 | 83 |
News Archive
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Research from Queen Mary University of London has revealed novel insights into the effects of chemotherapy on the tumor microenvironment (TME).
The Wall Street Journal on Wednesday examined how WellPoint CEO Angela Braly "is attempting a delicate balancing act: raising premiums enough to placate investors but not so much as to send customers fleeing elsewhere."
Though a small group of proteins, the family called Ras controls a large number of cellular functions, including cell growth, differentiation, and survival. And because the protein has a hand in cellular division, mutated Ras, which can be detected in one-third of all tumors, contributes to many human cancers by allowing for the rapid growth of diseased cells.
› Verified 5 days ago
Entity Name | Mc Diagnostic Of Connecticut, P.c. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1386821932 PECOS PAC ID: 0941382113 Enrollment ID: O20080126000057 |
News Archive
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Research from Queen Mary University of London has revealed novel insights into the effects of chemotherapy on the tumor microenvironment (TME).
The Wall Street Journal on Wednesday examined how WellPoint CEO Angela Braly "is attempting a delicate balancing act: raising premiums enough to placate investors but not so much as to send customers fleeing elsewhere."
Though a small group of proteins, the family called Ras controls a large number of cellular functions, including cell growth, differentiation, and survival. And because the protein has a hand in cellular division, mutated Ras, which can be detected in one-third of all tumors, contributes to many human cancers by allowing for the rapid growth of diseased cells.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Manhouly Phouthachack, 839 Farmington Ave, Bristol, CT 06010-3922 Ph: (866) 389-2727 | Manhouly Phouthachack, 839 Farmington Ave, Bristol, CT 06010-3922 Ph: (866) 389-2727 |
News Archive
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Research from Queen Mary University of London has revealed novel insights into the effects of chemotherapy on the tumor microenvironment (TME).
The Wall Street Journal on Wednesday examined how WellPoint CEO Angela Braly "is attempting a delicate balancing act: raising premiums enough to placate investors but not so much as to send customers fleeing elsewhere."
Though a small group of proteins, the family called Ras controls a large number of cellular functions, including cell growth, differentiation, and survival. And because the protein has a hand in cellular division, mutated Ras, which can be detected in one-third of all tumors, contributes to many human cancers by allowing for the rapid growth of diseased cells.
› Verified 5 days ago
Jennifer Lauren Hohman, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 839 Farmington Ave, Bristol, CT 06010 Phone: 816-786-0582 | |
Miss Danielle Grillo, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 61 Bradley St, Suite 1, Bristol, CT 06010 Phone: 860-314-6898 | |
Christie Lee Vardhami, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 420 N Main St, Bristol, CT 06010 Phone: 860-583-5858 | |
Lynne M Whitney, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 25 Newell Rd Ste E36, Bristol, CT 06010 Phone: 860-583-9252 Fax: 860-585-9848 | |
Margaret E Weir, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 102 North St, Bristol, CT 06010 Phone: 860-314-2082 Fax: 860-314-8133 | |
Julie Sacharko, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 41 Brewster Rd, Bristol, CT 06010 Phone: 860-585-3313 Fax: 860-585-3500 | |
Holly Fitzgerald, DNP, APRN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 625 Clark Ave, Bristol, CT 06010 Phone: 860-583-7700 |